## Induced Pluripotent Stem Cells from Subjects with Lesch-Nyhan Disease

Diane J. Sutcliffe,<sup>1\*</sup> Ashok R. Dinasarapu,<sup>2\*</sup> Jasper E. Visser,<sup>3,4</sup> Joery den Hoed,<sup>1</sup> Fatemeh Seifar,<sup>1,5</sup> Piyush Joshi,<sup>1</sup> Irene Ceballos-Picot,<sup>6</sup> Tejas Sardar,<sup>1</sup> Ellen J. Hess,<sup>1,5,7</sup> Yan V. Sun,<sup>8</sup> Zhexing Wen,<sup>1,9,10</sup> Michael E. Zwick,<sup>2,11</sup> H. A. Jinnah<sup>1,2,5,11.\*</sup>

- 1. Department of Neurology; Emory University School of Medicine, Atlanta, GA 30322
- 2. Department of Human Genetics; Emory University School of Medicine, Atlanta, GA 30322
- 3. Department of Neurology; Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center; Nijmegen, The Netherlands
- 4. Department of Neurology, Amphia Hospital, Breda, The Netherlands
- 5. Neurosciences Graduate Program, Graduate Division of Biological and Biomedical Sciences, Laney Graduate School, Emory University, 30322
- 6. Laboratoire de Biochimie Métabolomique et Protéomique; Hôpital Universitaire Necker
- 7. Department of Pharmacology and Chemical Biology; Emory University School of Medicine, Atlanta, GA 30322
- 8. Department of Epidemiology; Emory University Rollins School of Public Health, Atlanta, GA. 30322
- 9. Department of Psychiatry & Behavioral Sciences; Emory University School of Medicine, Atlanta, GA 30322
- 10. Department of Cell Biology; Emory University School of Medicine, Atlanta, GA 30322
- 11. Department of Pediatrics: Emory University School of Medicine, Atlanta, GA 30322

\*Co-First Authors

## \*Correspondence:

H. A. Jinnah, M.D., Ph.D. Professor, Departments of Neurology, Human Genetics & Pediatrics Emory University, 101 Woodruff Circle, 6305 Woodruff Memorial Building Atlanta GA, 30322 E-mail: hjinnah@emory.edu

## **Supplementary Material**

Supplementary Figure 1. Gene sequencing results for confirmation of LND gene variants.

Supplementary Figure 2. Karyotypes for each LND and control line.

Supplementary Figure 3. Quantitative PCR confirmation of selected findings from RNAseq.

Supplementary Figure 4. Western blot confirmation of selected findings from protemics.





Control Karyotypes		LND Kary	LND Karyotypes	
C1.02	C1.03	L2.09	L2.12	
And a second sec	annen an			
			<b>JE DA 20</b> EG EG DG EB	
	19 20 21 22 X Y		88 8¢ 36 68 8 9 19 20 21 22 X Y	
C2.04	C2.06	L3.29	L3.30	
	1 7 1 1 1		Control of the contro	
and a second sec	71 mi ne ac se si se	anno anno anno anno anno anno anno anno		
ês ês 30 m es 65 00			22 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
◎ 28 高品 (25 日 19 28 21 22 × Y	19 20 21 22 X Y		2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
C3.05	C3.08	L1.02	L1.04	
764 1230	Land Control of Contro	Annual and a second	And a second sec	
) >5 16 16 76 8 11	「 の の の の の の の の の の の の の		onno anter a contra con	
KN Is >< II R	· · · · · · · · · · · · · · · · · · ·	<b>御殿 御殿 御殿 </b> 19 19 19 19 19 19 19 19 19 19 19 19 19	9 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	
2 2 2 2 2 2 2 X Y	<ul> <li>(1) 20</li> <li>(1) 20</li> <li>(2) 21</li> <li>(2) 22</li> <li>(2) 2</li> <li>(2) 2</li></ul>	19 28 21 22 X Y	िति वैद्धि संस्कृति विद्यु	

## Supplementary Figure 2. Karyotypes for each LND and control line

**Control Karyotypes** 



Supplementary Figure 4. Western blot confirmation of selected findings from proteomics.

